AllPennyStocks.com Biotech ETF (CANC) Hits New 52-Week High
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Biotech ETF (CANC) Hits New 52-Week High

Tema Oncology ETF CANC is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has surged 72.8% from its 52-week low price of $26.24 per share.

Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.

CANC in Focus

The Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The CANC ETF consists of 58 total holdings, with the top 10 constituting 40.20% of the fund's assets. The leading holdings include Revolution Medicines Inc (6.02%), Eli Lilly & Co (5.01%), and Cogent Biosciences Inc (4.99%). The product charges 75 bps in annual fees.

Why the Move?

Merck and Moderna recently announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected Stage IIB-IV melanoma. Moderna stock surged 177% on Aug. 19, 2026 while Merck shares gained 12.6% on the day. The news acted as a cornerstone for the whole cancer investing space, boosting the pure-play fund.

More Gains Ahead?

The ETF gained over 3% on Aug. 19, 2026. CANC might continue its strong performance in the near term, with a positive weighted alpha of 66.73 (per Barchart.com), which hints at a rally.

Boost Your Portfolio with Our Top ETF Insights

Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.

Don’t miss out on this valuable resource. It’s free!

Get it now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Other Penny Stock Movers

A $1 Billion Crypto Deal Sends This Microcap Surging
The Scarcest Asset in Western Gold Exploration Is the Calendar
This Microcap Just Pulled Core From One of Copper's Last Frontiers
Most Popular
{{ index + 1 }}


Back to Top